WO2023156675A1 - Process for purification of linagliptin - Google Patents

Process for purification of linagliptin Download PDF

Info

Publication number
WO2023156675A1
WO2023156675A1 PCT/EP2023/054282 EP2023054282W WO2023156675A1 WO 2023156675 A1 WO2023156675 A1 WO 2023156675A1 EP 2023054282 W EP2023054282 W EP 2023054282W WO 2023156675 A1 WO2023156675 A1 WO 2023156675A1
Authority
WO
WIPO (PCT)
Prior art keywords
linagliptin
process according
organic solvent
mixture
ketone
Prior art date
Application number
PCT/EP2023/054282
Other languages
French (fr)
Inventor
Kaja Gosak
Davor Kidemet
Tone KRAŠOVEC
Ulcnik JOŽICA
Original Assignee
Krka, D.D., Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka, D.D., Novo Mesto filed Critical Krka, D.D., Novo Mesto
Publication of WO2023156675A1 publication Critical patent/WO2023156675A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Definitions

  • the present invention relates to a process for purification of linagliptin.
  • Linagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor used to treat diabetes mellitus type 2.
  • DPP-IV dipeptidyl peptidase-IV
  • the structural formula (I) of linagliptin is
  • Linagliptin has been disclosed in the patent application W02004018468 which describes a process for the preparation of linagliptin involving deprotection of tert-butyloxycarbonyl (Boc) protected linagliptin followed by purification using chromatography. The process is represented in Scheme 1.
  • WO2013098775 describes a process that does not involve the deprotection step and wherein linagliptin is directly obtained from a compound of formula (III). The process is represented in Scheme 3.
  • WO2016207364 also describes a process that does not involve a protection and deprotection of 3-aminopiperidine moiety.
  • the process uses iodine or chlorine instead of bromine as the leaving group and is represented in Scheme 4.
  • the inventors of the present invention have found a simple process for removal of impurity A present in linagliptin.
  • the invention is based on the finding that impurity A reacts faster with acyl halides, organic acid anhydrides and sulfonyl halides than linagliptin, which enables derivatization of impurity A and its removal from linagliptin by extraction.
  • the object of the present invention is a process for purification of linagliptin comprising subjecting linagliptin, comprising impurity A (impurity A), to a derivatization agent to produce a compound of formula (B)
  • R is acyl, SO2R 1 or CO2R 1 ; R 1 is unsubstituted or substituted hydrocarbon group; and removing the compound of formula (B) from linagliptin.
  • Acyl can be e.g. C(O)R 1 ; R 1 being unsubstituted or substituted hydrocarbon group.
  • R 1 can be unsubstituted or substituted alkyl, cycloalkyl, aryl or arylalkyl hydrocarbon group.
  • R 1 can for example comprise from 1 to 12 carbon atoms, in particular from 2 to 8 carbon atoms.
  • the process comprises the following steps: a) dissolving linagliptin, (said linagliptin) comprising impurity A, in the first organic solvent to form linagliptin organic solution; or preparing linagliptin reaction mixture by reacting 8-halo-7-(but-2-yn-l- yl)-3-methyl-l-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-lH- purine-2, 6-dione with 3-aminopiperidine in the first organic solvent; b) adding a derivatization agent to the linagliptin organic solution or linagliptin reaction mixture and mixing the obtained mixture; c) adding an acidic aqueous solution to the mixture and mixing the mixture; d) separating the liquid phases and removing the organic phase; e) adding the second organic solvent and a base to the aqueous phase and mixing the obtained mixture; f) separating the liquid phases and removing the
  • Step d) can be in particular separating the liquid phases (e.g. organic liquid phase and aqueous liquid phase) from the mixture prepared in step c), and subsequently removing the organic phase.
  • step d) can be allowing separation of the liquid phases from the mixture prepared in step c), and subsequently removing the organic phase.
  • Step f) can be in particular separating the liquid phases (e.g. organic liquid phase and aqueous liquid phase) from the mixture comprising the second organic solvent (e.g. prepared in step e)) and removing the aqueous phase.
  • step f) can be allowing separation of the liquid phases from the mixture comprising the second organic solvent (e.g. prepared in step e)) and removing the aqueous phase.
  • the amount of impurity A present in linagliptin can be determined by a chromatographic method such as gas chromatography (GC) or high- performance liquid chromatography (HPLC).
  • the chromatographic method is HPLC.
  • the amount of impurity A and other impurities in the examples of the present invention were determined via high performance liquid chromatography (HPLC), by using a Titan C18 column (100 x 2.1 mm i.d., 1.9 pm particles). Any other equivalent column with the reverse phase C18 as stationary phase may also be applied. Gradient elution using mobile phase A (0.15 % trifluoroacetic acid in water) and mobile phase B (acetonitrile) was applied. Before use, both mobile phases were degassed and filtered over a 0.45 pm filter.
  • HPLC results are expressed in terms of peak area %.
  • the amount of impurity A present in linagliptin is usually not higher than 1 % (w/w).
  • the derivatization agent which reacts with impurity A is preferably added in stoichiometric excess with respect to impurity A.
  • the derivatization agent can be added directly to the reaction mixture comprising linagliptin without prior isolation of linagliptin.
  • the derivatization agent can be added in an amount of 1-20 mol %, preferably 3-15 mol % and most preferably 5-12 mol % with respect to linagliptin (in particular with respect to the molar amount of linagliptin).
  • the temperature at which the derivatization takes place is not limited but is preferably a room temperature. Room temperature can be for example 18°C to 25°C, optionally 20°C to 23°C, especially 22°C.
  • the derivatization agent can be selected from the group comprising acyl halides, organic acid anhydrides and/or sulfonyl halides.
  • the derivatization agent is selected from acyl chlorides, carboxylic anhydrides and/or sulfonyl chlorides. More preferably, the derivatization agent is selected from sulfonyl chlorides and/or di-tert-butyl dicarbonate (Boc anhydride). Even more preferably, the derivatization agent is a sulfonyl chloride. Still even more preferably, the derivatization agent is p-toluenesulfonyl chloride and/or benzenesulfonyl chloride. Most preferably, the derivatization agent is p- toluenesulfonyl chloride.
  • compound (B) wherein R- is when using p-toluenesulfonyl chloride as derivatization agent, compound (B) wherein R- is can be obtained.
  • R- is can be obtained.
  • R-Hal when using an acyl halide R-Hal (R being acyl, and Hal can be selected from F, Cl, Br, I, especially can be Cl) as derivatization agent, a compound wherein R is acyl can be obtained.
  • R 1 -O-C(O)-O-C(O)- O-R 1 when using an organic acid anhydride R 1 -O-C(O)-O-C(O)- O-R 1 , R 1 being unsubstituted or substituted hydrocarbon group), as derivatization agent, a compound (B), wherein R is CO2 1 can be obtained.
  • Hal-SChR 1 as derivatization agent
  • Hal can be selected from F, Cl, Br, I, especially can be Cl
  • a compound (B), wherein R is SO2R 1 can be obtained.
  • the first organic solvent should not react with the derivatization agent and should be immiscible or partially miscible in water and can be selected from the group consisting of a C4-C10 ketone, such as methyl isobutyl ketone (MIBK), 2-butanone (MEK), diisobutyl ketone; a hydrocarbon, such as benzene, toluene, hexane, xylene, ethylbenzene; an ether, such as diethyl ether; and/or halogenated hydrocarbon such as dichloromethane.
  • the first organic solvent is a C4-C10 ketone.
  • a C4-C10 ketone can be selected from C4 ketone, C5 ketone, C6 ketone, C7 ketone, C8 ketone, C9 ketone, CIO ketone, and mixtures thereof. More preferably, the first organic solvent is 2- butanone, methyl isobutyl ketone, and/or diisobutyl ketone. Most preferably, the first organic solvent is methyl isobutyl ketone.
  • the first organic solvent does not react with the derivatization agent (especially at the temperature at which the derivatization takes place). In an embodiment, the first organic solvent is immiscible with water or partially miscible in water. In an embodiment, the first organic solvent does not react with the derivatization agent (especially at the temperature at which the derivatization takes place) and is immiscible with water or partially miscible in water.
  • the second organic solvent should be immiscible or partially miscible in water and can be selected from the group consisting of a C4-C10 ketone, such as methyl isobutyl ketone (MIBK), 2-butanone (MEK), diisobutyl ketone; a hydrocarbon, such as benzene, toluene, hexane, xylene, ethylbenzene; an ether, such as diethyl ether; a C4-C10 alcohol, such as 2-butanol; and/or halogenated hydrocarbon, such as dichloromethane.
  • a C4-C10 ketone such as methyl isobutyl ketone (MIBK), 2-butanone (MEK), diisobutyl ketone
  • a hydrocarbon such as benzene, toluene, hexane, xylene, ethylbenzene
  • an ether such as diethy
  • a C4-C10 ketone can be selected from C4 ketone, C5 ketone, C6 ketone, C7 ketone, C8 ketone, C9 ketone, CIO ketone, and mixtures thereof.
  • a C4-C10 alcohol can be selected from C4 alcohol, C5 alcohol, C6 alcohol, C7 alcohol, C8 alcohol, C9 alcohol, CIO alcohol, and mixtures thereof.
  • the second organic solvent is a C4-C10 alcohol and/or a hydrocarbon. More preferably, the second organic solvent is 2-butanol and/or toluene. Most preferably, the second organic solvent is toluene. In an embodiment, the second organic solvent is immiscible with water or partially miscible in water. Both the first organic solvent and the second organic solvent can be immiscible with water or partially miscible in water.
  • the acidic aqueous solution comprises water and an acid.
  • the acid can be selected from inorganic acids and/or organic acids.
  • the acid can be selected from hydrochloric acid, sulfuric acid, acetic acid, citric acid, tartaric acid, oxalic acid and/or formic acid.
  • the acid is acetic acid, citric acid and/or tartaric acid, and most preferably, the acid is citric acid.
  • the pH of the aqueous phase after addition of the acid in step c) is preferably below 4.
  • the base can be inorganic or organic.
  • the base is inorganic and can be selected from alkali metal or alkaline earth metal carbonates, bicarbonates, hydroxides, alkoxides, hydrides, ammonia and the like or mixture thereof. More preferably, the base is selected from sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, lithium hydroxide, sodium alkoxide, potassium alkoxide, sodium carbonate, potassium carbonate, calcium carbonate, magnesium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, calcium bicarbonate, magnesium bicarbonate and the like. Most preferably, the base is sodium hydroxide.
  • the base is preferably added as an aqueous solution. The pH of the aqueous phase after addition of the base in step e) is preferably above 10.
  • the most preferable aspect of the present invention is a process wherein the derivatization agent is p-toluenesulfonyl chloride and the first organic solvent is methyl isobutyl ketone.
  • R is acyl, SO2R 1 or CO2R 1 ; R 1 is unsubstituted or substituted hydrocarbon group.
  • R is tert-butoxycarbonyl or SO2R 1 ; R 1 is unsubstituted or substituted hydrocarbon group.
  • R is SO2R 1 ; R 1 is unsubstituted or substituted hydrocarbon group.
  • R is p-toluenesulfonyl or benzenesulfonyl.
  • R is p- toluenesulfonyl, which is depicted as formula (C)
  • Still another aspect of the present invention is use of the compound of formula (B) in the process for purification of linagliptin.
  • Preferred aspect of the present invention is a compound of formula (C) and its use in the process for purification of linagliptin, especially for the removal of impurity A.
  • Yet another aspect of the present invention is linagliptin purified by the process of the present invention.
  • derivatization agent selected from acyl halides, organic acid anhydrides, sulfonyl halides, and mixtures thereof for reducing the content of impurity A in a solution comprising linagliptin, solvent (preferably organic solvent, more preferably first organic solvent as defined herein supra), and impurity A.
  • derivatization agent selected from acyl halides, organic acid anhydrides, sulfonyl halides, and mixtures thereof for (partially or completely) removing impurity A from a solution comprising linagliptin, solvent (preferably organic solvent, more preferably first organic solvent as defined herein supra), and impurity A.
  • reaction vessel 75 g of 8-bromo-7-(but-2-yn-l-yl)-3-methyl-3,7-dihydro- lH-purine-2, 6-dione and 51.06 g of 2-(chloromethyl)-4-methylquinazoline and 375 mL of N-methyl-2-pyrrolidone is added.
  • Suspension is heated to 90 °C and 45.35 g of potassium carbonate is added.
  • Reaction mixture is heated at 90 °C for 3 h, then it is slowly cooled to 60 °C and mixture of 450 mL of ethanol and 412 mL of water is added dropwise.
  • reaction mixture is heated at 60 °C for 1 h and afterwards it is cooled to room temperature and mixed for 3 h.
  • Precipitate is filtered and washed with mixture of 150 mL of ethanol and 150 mL of water, and then with mixture of 300 ml of ethanol and 300 mL of water.
  • the solution is cooled to room temperature, 100 mL of 6% citric acid is added, mixed, and phases are separated. Aqueous phase is washed with mixture of 30 mL of toluene and 10 mL of 2-butanol, then 100 mL of 2-butanol is added. With 10% NaOH( aq ) pH is corrected above 10, then phases are separated and water phase is discarded. Two times half of solvent in the mixture is evaporated and replaced with the same volume of fresh 2-butanol until water content in the mixture is below 2 %. The mixture is mixed at room temperature few hours, filtered and the residue is washed with 2-butanol. The product is dried in a vacuum drier at 40 °C to obtain 6.32g of linagliptin with 99.07 % HPLC purity and with 0.71 % of impurity A.
  • the obtained solution is cooled to room temperature and 900 mg of p-toluenesulfonyl chloride is added to the solution.
  • the mixture is mixed for 30 minutes, then 200 mL 5 % aqueous solution of citric acid is added, mixed and phases are separated.
  • Aqueous phase is washed with mixture of 60 mL of toluene and 30 mL of 2-butanol, then 300 mL of toluene is added. With 20 % NaOH(aq) pH is corrected above 10, then phases are separated.
  • Organic phase is washed with 50 mL of 5 % aqueous solution of NaCI. Then 0.5 g of active charcoal is added and mixed for 15 min at 40 - 50 °C.
  • the obtained solution is cooled to room temperature and 582 pL of benzenesulfonyl chloride is added to the solution.
  • the mixture is mixed for 30 minutes, then 200 mL 5% aqueous solution of citric acid is added, mixed and phases are separated.
  • Aqueous phase is washed with mixture of 80 mL of toluene and 20 mL of 2-butanol, then 200 mL of toluene is added. With 20 % NaOH( aq ) pH is corrected above 10, then phases are separated.
  • Organic phase is washed with 50 mL of 5% aqueous solution of NaCI after 0.5 g of active charcoal is added and mixed for 15 min at 40 - 50 °C.
  • the solution is cooled to room temperature, 100 mL of 6% acetic acid is added, mixed, and phases are separated. Aqueous phase is washed with mixture of 30 mL of toluene and 10 mL of 2-butanol, then 100 mL of 2-butanol is added. With 10 % NaOH pH is corrected above 10, then phases are separated. Two times half of solvent in the mixture is evaporated and is replaced with the same volume of fresh 2-butanol, until water content in the mixture is below 2%. The mixture is mixed at room temperature few hours, filtered and washed with 2-butanol.
  • the solution is cooled to room temperature and 0.92 g of di-te/t-butyl dicarbonate is added to the solution.
  • the mixture is mixed for 30 minutes, then 100 mL of 6% aqueous solution of acetic acid is added, mixed and phases are separated.
  • Aqueous phase is washed with 40 mL of toluene, then 100 mL of 2-butanol is added. With 10% NaOH pH is corrected above 10, then phases are separated. Two times half of solvent in the organic phase is evaporated and is replaced with the same volume of fresh 2-butanol, until water content in the mixture is below 2%.
  • the mixture is mixed at room temperature few hours, filtered and washed with 2-butanol.
  • linagliptin (with 0.56 % of impurity A) 75 mL of MIBK is added. Suspension is heated to reflux until clear solution is obtained. After the solution is cooled to room temperature, 115 mg of di-tert-butyl dicarbonate is charged. The reaction mixture is mixed for 30 min. Then, 50 mL of 6 % aqueous solution of acetic acid is added and phases are separated. The aqueous phase is washed with 20 mL of toluene. 50 mL of 2-butanol is added to the aqueous phase and pH is corrected above 10 with 10% solution of NaOH( aq ) and phases are separated.
  • a vessel 150 g of 8-bromo-7-(but-2-yn-l-yl)-3-methyl-l-((4- methylquinazolin-2-yl)methyl)-3,7-dihydro-lH-purine-2, 6-dione 60.14 g of 3-aminopiperidine dihydrochloride and 160.06 g of potassium carbonate are charged. 1500 mL of methyl isobutyl ketone and 3 mL of water are added and mixture is heated to 90 - 100 °C. Reaction is monitored with TLC and when completed, hot reaction mixture is filtered and salts on the filter are washed with methyl isobutyl ketone.
  • the obtained solution is cooled to room temperature and 5.4 g of p-toluenesulfonyl chloride are added to the solution.
  • the mixture is mixed for 30 minutes, then 1500 mL 5 % aqueous solution of citric acid is added, mixed and phases are separated.
  • Aqueous phase is washed with mixture of 450 mL of toluene and 150 mL of 2-butanol, then 2250 mL of toluene is added. With 10 % NaOH( aq ) pH is corrected above 10 (430 ml of solution used), then phases are separated.
  • the organic phase is filtered and concentrated by distillation to approximately 600 ml.

Abstract

The present invention relates to a process for purification of linagliptin. Furthermore, the present application pertains to linagliptin purified by this process, as well as to a novel compound and its use.

Description

PROCESS FOR PURIFICATION OF LINAGLIPTIN
FIELD OF THE INVENTION
The present invention relates to a process for purification of linagliptin.
BACKGROUND OF THE INVENTION
Linagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor used to treat diabetes mellitus type 2. The structural formula (I) of linagliptin is
Figure imgf000002_0001
Linagliptin has been disclosed in the patent application W02004018468 which describes a process for the preparation of linagliptin involving deprotection of tert-butyloxycarbonyl (Boc) protected linagliptin followed by purification using chromatography. The process is represented in Scheme 1.
Figure imgf000003_0001
Scheme 1
Alternative process for preparation of linagliptin involving deprotection of phthalimide protected linagliptin is disclosed in W02006048427. The process is represented in Scheme 2.
Figure imgf000003_0002
Scheme 2
WO2013098775 describes a process that does not involve the deprotection step and wherein linagliptin is directly obtained from a compound of formula (III). The process is represented in Scheme 3.
Figure imgf000004_0001
Scheme 3
WO2016207364 also describes a process that does not involve a protection and deprotection of 3-aminopiperidine moiety. The process uses iodine or chlorine instead of bromine as the leaving group and is represented in Scheme 4.
Figure imgf000004_0002
Scheme 4 DETAILED DESCRIPTION OF THE INVENTION
The synthetic routes for linagliptin that do not require protection of 3- aminopiperidine moiety are shorter but generate increased amount of impurity A, which is difficult to remove by conventional processes.
Figure imgf000005_0001
(impurity A)
The inventors of the present invention have found a simple process for removal of impurity A present in linagliptin. The invention is based on the finding that impurity A reacts faster with acyl halides, organic acid anhydrides and sulfonyl halides than linagliptin, which enables derivatization of impurity A and its removal from linagliptin by extraction.
The object of the present invention is a process for purification of linagliptin comprising subjecting linagliptin, comprising impurity A
Figure imgf000005_0002
(impurity A), to a derivatization agent to produce a compound of formula (B)
Figure imgf000006_0001
wherein R is acyl, SO2R1 or CO2R1; R1 is unsubstituted or substituted hydrocarbon group; and removing the compound of formula (B) from linagliptin. Acyl can be e.g. C(O)R1; R1 being unsubstituted or substituted hydrocarbon group.
R1 can be unsubstituted or substituted alkyl, cycloalkyl, aryl or arylalkyl hydrocarbon group. R1 can for example comprise from 1 to 12 carbon atoms, in particular from 2 to 8 carbon atoms.
Preferably, the process comprises the following steps: a) dissolving linagliptin, (said linagliptin) comprising impurity A, in the first organic solvent to form linagliptin organic solution; or preparing linagliptin reaction mixture by reacting 8-halo-7-(but-2-yn-l- yl)-3-methyl-l-((4-methylquinazolin-2-yl)methyl)-3,7-dihydro-lH- purine-2, 6-dione with 3-aminopiperidine in the first organic solvent; b) adding a derivatization agent to the linagliptin organic solution or linagliptin reaction mixture and mixing the obtained mixture; c) adding an acidic aqueous solution to the mixture and mixing the mixture; d) separating the liquid phases and removing the organic phase; e) adding the second organic solvent and a base to the aqueous phase and mixing the obtained mixture; f) separating the liquid phases and removing the aqueous phase; and g) isolating linagliptin from the organic phase. Linagliptin organic solution (e.g. formed in step a)) can be in particular a solution comprising or consisting of linagliptin, impurity A, and the first organic solvent.
Step d) can be in particular separating the liquid phases (e.g. organic liquid phase and aqueous liquid phase) from the mixture prepared in step c), and subsequently removing the organic phase. Especially, step d) can be allowing separation of the liquid phases from the mixture prepared in step c), and subsequently removing the organic phase.
Step f) can be in particular separating the liquid phases (e.g. organic liquid phase and aqueous liquid phase) from the mixture comprising the second organic solvent (e.g. prepared in step e)) and removing the aqueous phase. Especially, step f) can be allowing separation of the liquid phases from the mixture comprising the second organic solvent (e.g. prepared in step e)) and removing the aqueous phase.
The formula of 8-halo-7-(but-2-yn-l-yl)-3-methyl-l-((4-methylquinazolin-2- yl)methyl)-3,7-dihydro-lH-purine-2, 6-dione is
Figure imgf000007_0001
, wherein X is a halogen.
The amount of impurity A present in linagliptin can be determined by a chromatographic method such as gas chromatography (GC) or high- performance liquid chromatography (HPLC). Preferably, the chromatographic method is HPLC. The amount of impurity A and other impurities in the examples of the present invention were determined via high performance liquid chromatography (HPLC), by using a Titan C18 column (100 x 2.1 mm i.d., 1.9 pm particles). Any other equivalent column with the reverse phase C18 as stationary phase may also be applied. Gradient elution using mobile phase A (0.15 % trifluoroacetic acid in water) and mobile phase B (acetonitrile) was applied. Before use, both mobile phases were degassed and filtered over a 0.45 pm filter.
Gradient elution
Figure imgf000008_0001
Flow rate: approximately 0.25 mL/min
Detection: UV 225 nm
Injection volume: 0.5 pL
Temperature: 25°C
HPLC results are expressed in terms of peak area %.
The amount of impurity A present in linagliptin is usually not higher than 1 % (w/w). The derivatization agent which reacts with impurity A is preferably added in stoichiometric excess with respect to impurity A. The derivatization agent can be added directly to the reaction mixture comprising linagliptin without prior isolation of linagliptin. The derivatization agent can be added in an amount of 1-20 mol %, preferably 3-15 mol % and most preferably 5-12 mol % with respect to linagliptin (in particular with respect to the molar amount of linagliptin). The temperature at which the derivatization takes place is not limited but is preferably a room temperature. Room temperature can be for example 18°C to 25°C, optionally 20°C to 23°C, especially 22°C.
The derivatization agent can be selected from the group comprising acyl halides, organic acid anhydrides and/or sulfonyl halides. Preferably, the derivatization agent is selected from acyl chlorides, carboxylic anhydrides and/or sulfonyl chlorides. More preferably, the derivatization agent is selected from sulfonyl chlorides and/or di-tert-butyl dicarbonate (Boc anhydride). Even more preferably, the derivatization agent is a sulfonyl chloride. Still even more preferably, the derivatization agent is p-toluenesulfonyl chloride and/or benzenesulfonyl chloride. Most preferably, the derivatization agent is p- toluenesulfonyl chloride.
In an embodiment, when using p-toluenesulfonyl chloride as derivatization agent, compound (B) wherein R- is
Figure imgf000009_0001
can be obtained. When using benzenesulfonyl chloride as derivatization agent, compound (B) wherein
R- is
Figure imgf000009_0002
can be obtained.
In an embodiment, when using an acyl halide R-Hal (R being acyl, and Hal can be selected from F, Cl, Br, I, especially can be Cl) as derivatization agent, a compound
Figure imgf000009_0003
wherein R is acyl can be obtained. In an embodiment, when using an organic acid anhydride R1-O-C(O)-O-C(O)- O-R1, R1 being unsubstituted or substituted hydrocarbon group), as derivatization agent, a compound (B), wherein R is CO2 1 can be obtained.
In an embodiment, when using a sulfonyl halide Hal-SChR1 as derivatization agent (Hal can be selected from F, Cl, Br, I, especially can be Cl), a compound (B), wherein R is SO2R1 can be obtained.
The first organic solvent should not react with the derivatization agent and should be immiscible or partially miscible in water and can be selected from the group consisting of a C4-C10 ketone, such as methyl isobutyl ketone (MIBK), 2-butanone (MEK), diisobutyl ketone; a hydrocarbon, such as benzene, toluene, hexane, xylene, ethylbenzene; an ether, such as diethyl ether; and/or halogenated hydrocarbon such as dichloromethane. Preferably, the first organic solvent is a C4-C10 ketone. A C4-C10 ketone can be selected from C4 ketone, C5 ketone, C6 ketone, C7 ketone, C8 ketone, C9 ketone, CIO ketone, and mixtures thereof. More preferably, the first organic solvent is 2- butanone, methyl isobutyl ketone, and/or diisobutyl ketone. Most preferably, the first organic solvent is methyl isobutyl ketone.
In an embodiment, the first organic solvent does not react with the derivatization agent (especially at the temperature at which the derivatization takes place). In an embodiment, the first organic solvent is immiscible with water or partially miscible in water. In an embodiment, the first organic solvent does not react with the derivatization agent (especially at the temperature at which the derivatization takes place) and is immiscible with water or partially miscible in water.
The second organic solvent should be immiscible or partially miscible in water and can be selected from the group consisting of a C4-C10 ketone, such as methyl isobutyl ketone (MIBK), 2-butanone (MEK), diisobutyl ketone; a hydrocarbon, such as benzene, toluene, hexane, xylene, ethylbenzene; an ether, such as diethyl ether; a C4-C10 alcohol, such as 2-butanol; and/or halogenated hydrocarbon, such as dichloromethane. A C4-C10 ketone can be selected from C4 ketone, C5 ketone, C6 ketone, C7 ketone, C8 ketone, C9 ketone, CIO ketone, and mixtures thereof. A C4-C10 alcohol can be selected from C4 alcohol, C5 alcohol, C6 alcohol, C7 alcohol, C8 alcohol, C9 alcohol, CIO alcohol, and mixtures thereof. Preferably, the second organic solvent is a C4-C10 alcohol and/or a hydrocarbon. More preferably, the second organic solvent is 2-butanol and/or toluene. Most preferably, the second organic solvent is toluene. In an embodiment, the second organic solvent is immiscible with water or partially miscible in water. Both the first organic solvent and the second organic solvent can be immiscible with water or partially miscible in water.
The acidic aqueous solution comprises water and an acid. The acid can be selected from inorganic acids and/or organic acids. For example, the acid can be selected from hydrochloric acid, sulfuric acid, acetic acid, citric acid, tartaric acid, oxalic acid and/or formic acid. Preferably, the acid is acetic acid, citric acid and/or tartaric acid, and most preferably, the acid is citric acid. The pH of the aqueous phase after addition of the acid in step c) is preferably below 4.
The base can be inorganic or organic. Preferably, the base is inorganic and can be selected from alkali metal or alkaline earth metal carbonates, bicarbonates, hydroxides, alkoxides, hydrides, ammonia and the like or mixture thereof. More preferably, the base is selected from sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, lithium hydroxide, sodium alkoxide, potassium alkoxide, sodium carbonate, potassium carbonate, calcium carbonate, magnesium carbonate, lithium carbonate, sodium bicarbonate, potassium bicarbonate, calcium bicarbonate, magnesium bicarbonate and the like. Most preferably, the base is sodium hydroxide. The base is preferably added as an aqueous solution. The pH of the aqueous phase after addition of the base in step e) is preferably above 10.
Preferable aspect of the present invention is a process wherein the derivatization agent is a sulfonyl chloride and the first organic solvent is a C4- C10 ketone. More preferable aspect of the present invention is a process wherein the derivatization agent is a sulfonyl chloride and the first organic solvent is methyl isobutyl ketone. The most preferable aspect of the present invention is a process wherein the derivatization agent is p-toluenesulfonyl chloride and the first organic solvent is methyl isobutyl ketone.
Another object of the present invention is a compound of formula (B)
Figure imgf000012_0001
wherein R is acyl, SO2R1 or CO2R1; R1 is unsubstituted or substituted hydrocarbon group. Preferably, R is tert-butoxycarbonyl or SO2R1; R1 is unsubstituted or substituted hydrocarbon group. More preferably, R is SO2R1; R1 is unsubstituted or substituted hydrocarbon group. Even more preferably, R is p-toluenesulfonyl or benzenesulfonyl. Most preferably, R is p- toluenesulfonyl, which is depicted as formula (C)
Figure imgf000013_0001
Still another aspect of the present invention is use of the compound of formula (B) in the process for purification of linagliptin. Preferred aspect of the present invention is a compound of formula (C) and its use in the process for purification of linagliptin, especially for the removal of impurity A.
Yet another aspect of the present invention is linagliptin purified by the process of the present invention.
According to yet another aspect, there is provided the use of derivatization agent selected from acyl halides, organic acid anhydrides, sulfonyl halides, and mixtures thereof for reducing the content of impurity A in a solution comprising linagliptin, solvent (preferably organic solvent, more preferably first organic solvent as defined herein supra), and impurity A.
According to yet another aspect, there is provided the use of derivatization agent selected from acyl halides, organic acid anhydrides, sulfonyl halides, and mixtures thereof for (partially or completely) removing impurity A from a solution comprising linagliptin, solvent (preferably organic solvent, more preferably first organic solvent as defined herein supra), and impurity A.
The invention is illustrated in more detail on the basis of the following nonlimiting examples. EXAMPLES
Example 1: Synthesis of 2-(chloromethyl)-4-methylquinazoline
Figure imgf000014_0001
10 g of l-(2-aminophenyl)ethan-l-one hydrochloride is suspended in 100 mL of chlorobenzene. Subsequently 7.76 g of AlCh and 11.06 mL of 2- chloroacetonitrile are added and reaction mixture is heated to 80 °C. Reaction is monitored with HPLC. When completed, the reaction mixture is cooled to room temperature and poured into 140 mL of water. After phases are separated, the aqueous phase is extracted with chlorobenzene. Combined organic phases are washed with saturated NaHCOs and the solvent is evaporated to obtain 10.31 g of 2-(chloromethyl)-4-methylquinazoline with 99.5 % HPLC purity.
Example 2: Synthesis of 8-bromo-3-methyl-3,7-dihydro-lH-purine-2, 6-dione
Figure imgf000014_0002
In a flask 25 g of 3-methyl-3,7-dihydro-lH-purine-2, 6-dione, 22.52 g of sodium acetate trihydrate and 52.94 g of pyridinium tribromide is combined and 100 mL of acetic acid is added. Reaction mixture is heated to 60°C and monitored with HPLC. When the reaction is completed the mixture is cooled to room temperature and 200 mL of water is added and mixed at room temperature for 2h. Suspension is filtered off and crude product is suspended in methanol and mixed at 60°C for lh, then it is cooled to 40°C and mixed for lh. Finally, the suspension is filtered and washed with methanol and vacuum dried at 40 °C to collect 32.28 g of 8-bromo-3-methyl-3,7-dihydro-lH-purine- 2, 6-dione with 99.5 % HPLC purity.
Example 3: Synthesis of 8-bromo-7-(but-2-yn-l-yl)-3-methyl-3,7-dihydro- lH-purine-2, 6-dione
Figure imgf000015_0001
In a flask 3 g of 8-bromo-3-methyl-3,7-dihydro-lH-purine-2, 6-dione is suspended in 30 mL of DMSO, subsequently 1.54g of sodium hydrogen carbonate is added and 1.28 mL of l-bromo-2-butine is added dropwise. Reaction mixture is heated to 30°C until reaction completion. 50 mL of water is added and is mixed for 2 h at room temperature. The product is filtered, washed with water and dried in vacuum drier at 40 °C to obtain 3.23 g of 8- bromo-7-(but-2-yn-l-yl)-3-methyl-3,7-dihydro-lH-purine-2, 6-dione.
Example 4: Synthesis of 8-bromo-7-(but-2-yn-l-yl)-3-methyl-l-((4- methylquinazolin-2-yl)methyl)-3,7-dihydro-lH-purine-2, 6-dione
Figure imgf000016_0001
In reaction vessel 75 g of 8-bromo-7-(but-2-yn-l-yl)-3-methyl-3,7-dihydro- lH-purine-2, 6-dione and 51.06 g of 2-(chloromethyl)-4-methylquinazoline and 375 mL of N-methyl-2-pyrrolidone is added. Suspension is heated to 90 °C and 45.35 g of potassium carbonate is added. Reaction mixture is heated at 90 °C for 3 h, then it is slowly cooled to 60 °C and mixture of 450 mL of ethanol and 412 mL of water is added dropwise. To the vessel a mixture of 30 mL of acetic acid and 37.5 mL of water is added dropwise at 60 °C. After completion, reaction mixture is heated at 60 °C for 1 h and afterwards it is cooled to room temperature and mixed for 3 h. Precipitate is filtered and washed with mixture of 150 mL of ethanol and 150 mL of water, and then with mixture of 300 ml of ethanol and 300 mL of water. Product is collected and dried in vacuum drier at 40 °C to obtain 104.9 g of 8-bromo-7-(but-2-yn-l-yl)-3-methyl-l-((4- methylquinazolin-2-yl)methyl)-3,7-dihydro-lH-purine-2, 6-dione with 99.3 % HPLC purity. Example 5: Synthesis of linagliptin
Figure imgf000017_0001
In a vessel 10 g of 8-bromo-7-(but-2-yn-l-yl)-3-methyl-l-((4- methylquinazolin-2-yl)methyl)-3,7-dihydro-lH-purine-2, 6-dione, 4.01 g of 3- aminopiperidine dihydrochloride and 10.65 g of potassium carbonate is charged. 100 mL of methyl isobutyl ketone is added and mixture is heated to 90 - 100 °C. Reaction is monitored with TLC and when completed, hot reaction mixture is filtered off and salts on the filter are washed with methyl isobutyl ketone. The solution is cooled to room temperature, 100 mL of 6% citric acid is added, mixed, and phases are separated. Aqueous phase is washed with mixture of 30 mL of toluene and 10 mL of 2-butanol, then 100 mL of 2-butanol is added. With 10% NaOH(aq) pH is corrected above 10, then phases are separated and water phase is discarded. Two times half of solvent in the mixture is evaporated and replaced with the same volume of fresh 2-butanol until water content in the mixture is below 2 %. The mixture is mixed at room temperature few hours, filtered and the residue is washed with 2-butanol. The product is dried in a vacuum drier at 40 °C to obtain 6.32g of linagliptin with 99.07 % HPLC purity and with 0.71 % of impurity A.
Example 6: Synthesis of linagliptin and purification with p-toluenesulfonyl chloride
Figure imgf000018_0001
In a vessel 19 g of 8-bromo-7-(but-2-yn-l-yl)-3-methyl-l-((4- methylquinazolin-2-yl)methyl)-3,7-dihydro-lH-purine-2, 6-dione, 7.62 g of 3- aminopiperidine dihydrochloride and 20.27 g of potassium carbonate is charged. 190 mL of methyl isobutyl ketone is added and mixture is heated to 90 - 100 °C. Reaction is monitored with TLC and when completed, hot reaction mixture is filtered and salts on the filter are washed with methyl isobutyl ketone. The obtained solution is cooled to room temperature and 900 mg of p-toluenesulfonyl chloride is added to the solution. The mixture is mixed for 30 minutes, then 200 mL 5 % aqueous solution of citric acid is added, mixed and phases are separated. Aqueous phase is washed with mixture of 60 mL of toluene and 30 mL of 2-butanol, then 300 mL of toluene is added. With 20 % NaOH(aq) pH is corrected above 10, then phases are separated. Organic phase is washed with 50 mL of 5 % aqueous solution of NaCI. Then 0.5 g of active charcoal is added and mixed for 15 min at 40 - 50 °C. The suspension is filtered and approximately 200 mL of toluene is distilled from the filtrate and cooled to 0 °C. Linagliptin starts to precipitate, suspension is filtered and washed with toluene. The product is dried in a vacuum drier at 40 °C to obtain 14.28 g of linagliptin. HPLC purity: 99.69 %, impurity A: 0.07 %. Example 7: Synthesis of linagliptin and purification with benzenesulfonyl chloride
Figure imgf000019_0001
In a vessel 20 g of 8-bromo-7-(but-2-yn-l-yl)-3-methyl-l-((4- methylquinazolin-2-yl)methyl)-3,7-dihydro-lH-purine-2, 6-dione, 8.02 g of 3- aminopiperidine dihydrochloride and 21.4 g of potassium carbonate is charged. 200 mL of methyl isobutyl ketone is added and mixture is heated to 90 - 100 °C. Reaction is monitored with TLC and when completed, hot reaction mixture is filtered and salts on the filter are washed with methyl isobutyl ketone. The obtained solution is cooled to room temperature and 582 pL of benzenesulfonyl chloride is added to the solution. The mixture is mixed for 30 minutes, then 200 mL 5% aqueous solution of citric acid is added, mixed and phases are separated. Aqueous phase is washed with mixture of 80 mL of toluene and 20 mL of 2-butanol, then 200 mL of toluene is added. With 20 % NaOH(aq) pH is corrected above 10, then phases are separated. Organic phase is washed with 50 mL of 5% aqueous solution of NaCI after 0.5 g of active charcoal is added and mixed for 15 min at 40 - 50 °C. Then, suspension is filtered and approximately 140 mL of toluene is distilled from the filtrate and cooled to 0 °C. Linagliptin starts to precipitate, suspension is filtered and wash with toluene. The product is dried in a vacuum drier at 40 °C to obtain 16.0 g of linagliptin with 99.60 % HPLC purity and with 0.05 % of impurity A. Example 8: Synthesis of linagliptin in DMSO
Figure imgf000020_0001
In a vessel 10 g of 8-bromo-7-(but-2-yn-l-yl)-3-methyl-l-((4- methylquinazolin-2-yl)methyl)-3,7-dihydro-lH-purine-2, 6-dione, 4.23 g of 3- aminopiperidine dihydrochloride and 6.12 g of sodium hydrogen carbonate is charged. 50 mL of dimethyl sulfoxide is added and mixture is heated to 90 - 100 °C. Reaction is monitored with TLC and when completed, hot reaction mixture is filtered and salts on the filter are washed with methyl isobutyl ketone. The solution is cooled to room temperature, 100 mL of 6% acetic acid is added, mixed, and phases are separated. Aqueous phase is washed with mixture of 30 mL of toluene and 10 mL of 2-butanol, then 100 mL of 2-butanol is added. With 10 % NaOH pH is corrected above 10, then phases are separated. Two times half of solvent in the mixture is evaporated and is replaced with the same volume of fresh 2-butanol, until water content in the mixture is below 2%. The mixture is mixed at room temperature few hours, filtered and washed with 2-butanol. The product is dried in a vacuum drier at 40 °C to obtain 6.36 g of linagliptin with 98.51 % HPLC purity and with 0.56 % of impurity A. Example 9: Synthesis of linagliptin and purification with di-tert-butyl dicarbonate
Figure imgf000021_0001
In a vessel 10 g of 8-bromo-7-(but-2-yn-l-yl)-3-methyl-l-((4- methylquinazolin-2-yl)methyl)-3,7-dihydro-lH-purine-2, 6-dione, 4.58 g of 3- aminopiperidine dihydrochloride and 7.61 g of potassium carbonate is charged. 100 mL of methyl isobutyl ketone (MIBK) is added and mixture is heated to reflux. Reaction is monitored with TLC and when completed, hot reaction mixture is filtered and salts on the filter are washed with MIBK. The solution is cooled to room temperature and 0.92 g of di-te/t-butyl dicarbonate is added to the solution. The mixture is mixed for 30 minutes, then 100 mL of 6% aqueous solution of acetic acid is added, mixed and phases are separated. Aqueous phase is washed with 40 mL of toluene, then 100 mL of 2-butanol is added. With 10% NaOH pH is corrected above 10, then phases are separated. Two times half of solvent in the organic phase is evaporated and is replaced with the same volume of fresh 2-butanol, until water content in the mixture is below 2%. The mixture is mixed at room temperature few hours, filtered and washed with 2-butanol. The product is dried in a vacuum drier at 40°C to obtain 8.00 g of linagliptin with 99.79% HPLC purity and with impurity A below detecting threshold. Example 10: Purification of linagliptin with benzenesulfonyl chloride
To 2 g of linagliptin (with 0.56 % of impurity A) 20 mL of MIBK is added. Suspension is heated to reflux until clear solution is obtained. After the solution is cooled to room temperature 54 pL of benzenesulfonyl chloride is charged. The reaction mixture is mixed for 30 min. Then, 20 mL of 6% aqueous solution of acetic acid is added, phases are separated and aqueous phase is washed with 5 mL of toluene. 20 mL of 2-butanol is added to the aqueous phase and pH is corrected above 10 with 10% solution of NaOH(aq) and phases are separated. Two times half of solvent in the organic phase is evaporated and is replaced with the same volume of fresh 2-butanol, until water content in the mixture is below 2 %. The mixture is mixed at room temperature few hours, filtered and washed with 2-butanol. The product is dried in a vacuum drier at 40 °C to obtain 1.28g of linagliptin with impurity A below detecting threshold.
Example 11 : Purification of linagliptin with di-tert-butyl dicarbonate
To 5 g of linagliptin (with 0.56 % of impurity A) 75 mL of MIBK is added. Suspension is heated to reflux until clear solution is obtained. After the solution is cooled to room temperature, 115 mg of di-tert-butyl dicarbonate is charged. The reaction mixture is mixed for 30 min. Then, 50 mL of 6 % aqueous solution of acetic acid is added and phases are separated. The aqueous phase is washed with 20 mL of toluene. 50 mL of 2-butanol is added to the aqueous phase and pH is corrected above 10 with 10% solution of NaOH(aq) and phases are separated. Two times half of solvent in the organic phase is evaporated and is replaced with the same volume of fresh 2-butanol, until water content in the mixture is below 2 %. The mixture is mixed at room temperature for several hours, filtered and washed with 2-butanol. The product is dried in a vacuum drier at 40 °C to obtain 3.18g of linagliptin with impurity A below detecting threshold.
Example 12: Synthesis of linagliptin and purification with p-toluenesulfonyl chloride
Figure imgf000023_0001
In a vessel 150 g of 8-bromo-7-(but-2-yn-l-yl)-3-methyl-l-((4- methylquinazolin-2-yl)methyl)-3,7-dihydro-lH-purine-2, 6-dione, 60.14 g of 3-aminopiperidine dihydrochloride and 160.06 g of potassium carbonate are charged. 1500 mL of methyl isobutyl ketone and 3 mL of water are added and mixture is heated to 90 - 100 °C. Reaction is monitored with TLC and when completed, hot reaction mixture is filtered and salts on the filter are washed with methyl isobutyl ketone. The obtained solution is cooled to room temperature and 5.4 g of p-toluenesulfonyl chloride are added to the solution. The mixture is mixed for 30 minutes, then 1500 mL 5 % aqueous solution of citric acid is added, mixed and phases are separated. Aqueous phase is washed with mixture of 450 mL of toluene and 150 mL of 2-butanol, then 2250 mL of toluene is added. With 10 % NaOH(aq) pH is corrected above 10 (430 ml of solution used), then phases are separated. The organic phase is filtered and concentrated by distillation to approximately 600 ml. 1800 ml of methanol is added and the mixture is concentrated to approximately 600 ml, this step being repeated once again. The mixture is then cooled to 25 °C in 1 h. Seeding crystals are added (0.75 g). Linagliptin starts to precipitate. The mixture is stirred at 25 °C for 1 h, then cooled to 3 °C in 3 h. After stirring for another 6 h at 3 °C the suspension is filtered and washed with 50 ml of methanol. The product is dried in a vacuum dryer at 40 °C to yield 118 g of linagliptin. HPLC purity: 99.82 %, impurity A: 0.02 %.

Claims

1. A process for purification of linagliptin comprising subjecting linagliptin, comprising impurity A
Figure imgf000025_0001
(impurity A), to a derivatization agent to produce a compound of formula (B)
Figure imgf000025_0002
wherein R is acyl, SO2R1 or CO2R1; R1 is unsubstituted or substituted hydrocarbon group; and removing the compound of formula (B) from linagliptin.
2. A process according to claim 1, comprising the following steps: a) dissolving linagliptin, comprising impurity A, in the first organic solvent to form linagliptin organic solution; or preparing linagliptin reaction mixture by reacting 8-halo-7-(but-2- yn-l-yl)-3-methyl-l-((4-methylquinazolin-2-yl)methyl)-3,7- dihydro-lH-purine-2, 6-dione with 3-aminopiperidine in the first organic solvent; b) adding a derivatization agent to the linagliptin organic solution or linagliptin reaction mixture and mixing the obtained mixture; c) adding an acidic aqueous solution to the mixture and mixing the mixture; d) separating the liquid phases and removing the organic phase; e) adding the second organic solvent and a base to the aqueous phase and mixing the obtained mixture; f) separating the liquid phases and removing the aqueous phase; and g) isolating linagliptin from the organic phase. The process according to claim 1, wherein the derivatization agent is selected from acyl halides, organic acid anhydrides and/or sulfonyl halides. The process according to claim 3, wherein the derivatization agent is selected from acyl chlorides, carboxylic anhydrides and/or sulfonyl chlorides. The process according to claim 4, wherein the derivatization agent is selected from sulfonyl chlorides and/or di-tert-butyl dicarbonate. The process according to claim 5, wherein the derivatization agent is a sulfonyl chloride. The process according to claim 6, wherein the derivatization agent is p- toluenesulfonyl chloride. The process according to claim 2, wherein the first organic solvent is selected from the group consisting of a C4-C10 ketone, a hydrocarbon, an ether, and/or halogenated hydrocarbon. The process according to claim 8, wherein the first organic solvent is a C4-C10 ketone. The process according to claim 9, wherein the first organic solvent is 2- butanone, methyl isobutyl ketone, and/or diisobutyl ketone. The process according to claim 10, wherein the first organic solvent is methyl isobutyl ketone. The process according to claim 2, wherein the second organic solvent is selected from the group consisting of a C4-C10 ketone, a hydrocarbon, an ether, a C4-C10 alcohol and/or halogenated hydrocarbon. The process according to claim 12, wherein the second organic solvent is a C4-C10 alcohol and/or a hydrocarbon. The process according to claim 1, wherein the derivatization agent is added in an amount of 1-20 mol % with respect to linagliptin. A compound of formula (B)
Figure imgf000028_0001
R1 is unsubstituted or substituted hydrocarbon group. The compound according to claim 15, wherein R is tert-butoxycarbonyl or SO2R.1; R1 is unsubstituted or substituted hydrocarbon group. The compound according to claim 16, wherein R is SO2R1; R1 is unsubstituted or substituted hydrocarbon group. The compound according to claim 17, wherein R is p-toluenesulfonyl or benzenesulfonyl. The compound according to claim 18, wherein R is p-toluenesulfonyl. Use of the compound of formula (B) of claim 15 in the process for purification of linagliptin. Linagliptin purified by the process of claim 1.
PCT/EP2023/054282 2022-02-21 2023-02-21 Process for purification of linagliptin WO2023156675A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SIP-202200021 2022-02-21
SI202200021 2022-02-21

Publications (1)

Publication Number Publication Date
WO2023156675A1 true WO2023156675A1 (en) 2023-08-24

Family

ID=85321165

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2023/054282 WO2023156675A1 (en) 2022-02-21 2023-02-21 Process for purification of linagliptin

Country Status (1)

Country Link
WO (1) WO2023156675A1 (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018468A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
WO2006048427A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim International Gmbh Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines
WO2013098775A1 (en) 2011-12-28 2013-07-04 Dr. Reddy's Laboratories Limited Improved process for preparation of pure linagliptin
WO2016207364A1 (en) 2015-06-25 2016-12-29 Boehringer Ingelheim International Gmbh Process for the preparation of a xanthine-based compound
CN105712995B (en) * 2014-12-05 2017-11-03 浙江京新药业股份有限公司 A kind of Li Gelieting purification process
WO2019219620A1 (en) * 2018-05-15 2019-11-21 Cambrex Profarmaco Milano S.R.L. Intermediates and processes for the preparation of linagliptin and its salts

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004018468A2 (en) 2002-08-21 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-amino-piperidin-1-yl]-xanthines, the production thereof and the use of the same as medicaments
WO2006048427A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim International Gmbh Method for producing chiral 8-(3-amino-piperidin-1-yl)-xanthines
WO2013098775A1 (en) 2011-12-28 2013-07-04 Dr. Reddy's Laboratories Limited Improved process for preparation of pure linagliptin
CN105712995B (en) * 2014-12-05 2017-11-03 浙江京新药业股份有限公司 A kind of Li Gelieting purification process
WO2016207364A1 (en) 2015-06-25 2016-12-29 Boehringer Ingelheim International Gmbh Process for the preparation of a xanthine-based compound
WO2019219620A1 (en) * 2018-05-15 2019-11-21 Cambrex Profarmaco Milano S.R.L. Intermediates and processes for the preparation of linagliptin and its salts

Similar Documents

Publication Publication Date Title
US7645880B2 (en) Processs for preparing N-alkylnaltrexone halides
CA2928242A1 (en) Process for the preparation of a pde4 inhibitor
US20110092719A1 (en) Preparation of Escitalopram, Its Salts and Intermediates
CA2919317A1 (en) Synthesis of biphenylalaninol via novel intermediates
US20100331546A1 (en) Method for optical resolution of alkyl piperidin-3-yl carbamate and intermediate therefor
US8378106B2 (en) Method for preparing argatroban monohydrate and a process for its synthesis
EP1919885B1 (en) Preparation of 2-amino-thiazole-5-carboxylic-acid derivatives
WO2015011609A1 (en) Process for the preparation of linagliptin and an intermediate thereof
WO2009139002A2 (en) An improved process for the preparation of solifenacin and its pharmaceutically acceptable salts thereof
JP5441883B2 (en) Method for producing galantamine
WO2023156675A1 (en) Process for purification of linagliptin
WO2009062036A2 (en) Processes for preparing levocetirizine and pharmaceutically acceptable salts thereof
CN105418477B (en) The method for reducing diastereoisomer impurity content in Lei Dipawei intermediate
JP6947354B2 (en) How to make linagliptin
US6987185B2 (en) Method for separating methyl 4-(2-chloro-4-fluorophenyl)-2-(3,5-difluoro-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidine-carboxylate-recemate
TWI826724B (en) Method for producing 1,5-benzothiazepine compounds
US7838700B2 (en) Recovery and recycling of chiral tartaric acid resolving agents
JP4319292B2 (en) Method for producing tert-butoxycarbonyl chloride
JP4721339B2 (en) Method for producing N-alkoxycarbonylamino acid
WO2011161646A2 (en) Process for the preparation of alvimopan or its pharmaceutically acceptable salt or solvate thereof
CN107337628B (en) Method for preparing levetiracetam
CN103562207A (en) Process for the preparation of 2-amino-9-((2-phenyl-1,3-dioxan-5-yloxy)methyl)-1h-purin-6(9h)-one compound useful in the preparation of valganciclovir
WO2015076346A1 (en) Method for producing optically active 2,6-dimethyltyrosine derivative
JP2008510717A (en) Process for producing levorphanol and related compounds
JP3884063B2 (en) Cefcapene pivoxil methanesulfonate

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23706593

Country of ref document: EP

Kind code of ref document: A1